Cirius Therapeutics Completes $40 Million Series A Financing to Fund Phase 2b Study of MSDC-0602K in NASH, Adds to Executive Team

SAN DIEGO and KALAMAZOO, Mich., April 11, 2017 /PRNewswire/ – Cirius Therapeutics, previously known as Octeta Therapeutics, announced today the completion of a Series A financing of up to $40 million led by Frazier Healthcare Partners […]

Read On ›

NeoChord Names J. Alex Martin Chairman of the Board

ST. LOUIS PARK, Minn., Jan. 23, 2017 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the appointment of […]

Read On ›

ProNAi Relaunched as Sierra Oncology to Advance DDR-Based Cancer Drugs

VANCOUVER, Jan. 9, 2017 /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced it has changed its corporate name to Sierra […]

Read On ›